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Abstract
Background
Respiratory failure is a leading cause of  neonatal mortality in the developing world. Bubble continuous positive airway pressure (bCPAP) 
is a safe, effective intervention for infants with respiratory distress and is widely used in developed countries. Because of  its high cost, 
bCPAP is not widely utilized in low-resource settings. We evaluated the performance of  a new bCPAP system to treat severe respiratory 
distress in a low resource setting, comparing it to nasal oxygen therapy, the current standard of  care.
Methods
We conducted a non-randomized convenience sample study to test the efficacy of  a low-cost bCPAP system treating newborns with 
severe respiratory distress in the neonatal ward of  Queen Elizabeth Central Hospital, in Blantyre, Malawi. Neonates weighing >1,000 g 
and presenting with severe respiratory distress who fulfilled inclusion criteria received nasal bCPAP if  a device was available; if  not, they 
received standard care. Clinical assessments were made during treatment and outcomes compared for the two groups.
Findings
87 neonates (62 bCPAP, 25 controls) were recruited. Survival rate for neonates receiving bCPAP was 71.0% (44/62) compared with 
44.0% (11/25) for controls. 65.5% (19/29) of  very low birth weight neonates receiving bCPAP survived to discharge compared to 
15.4% (1/13) of  controls. 64.6% (31/48) of  neonates with respiratory distress syndrome (RDS) receiving bCPAP survived to discharge, 
compared to 23.5% (4/17) of  controls. 61.5% (16/26) of  neonates with sepsis receiving bCPAP survived to discharge, while none of  
the seven neonates with sepsis in the control group survived.
Interpretation
Use of  a low-cost bCPAP system to treat neonatal respiratory distress resulted in 27% absolute improvement in survival. The beneficial 
effect was greater for neonates with very low birth weight, RDS, or sepsis. Implementing appropriate bCPAP devices could reduce 
neonatal mortality in developing countries.
Introduction
Severe respiratory distress is a common and serious 
complication of  premature birth, neonatal pneumonia, and 
neonatal sepsis, which together account for over one-half  of  
all neonatal deaths globally.1 More than 50% of  babies born 
at ≤31 weeks of  gestation will develop respiratory distress 
syndrome (RDS).2 Respiratory distress is associated with 
over 80% of  cases of  neonatal pneumonia3 and most cases 
of  neonatal sepsis.4
In the developed world, respiratory support is provided to 
neonates using either mechanical ventilation or Continuous 
Positive Airway Pressure (CPAP). Unfortunately, ventilators 
and CPAP machines are too expensive and technically 
complex for many resource-limited settings.5 As a result, 
respiratory illness remains one of  the most common causes 
of  neonatal death in the developing world.
CPAP is a gentle and effective tool to treat even preterm 
and low birth weight infants in respiratory distress.6–11 Well-
resourced hospitals use ventilators, stand-alone CPAP devices, 
or tubing, wall air and oxygen to set up CPAP at the bedside.8 
In bubble CPAP (bCPAP), pressure is safely regulated 
by submerging the end of  the tubing in a bottle of  water. 
The depth of  water determines the pressure in the system. 
This pressure helps recruit alveoli and increase functional 
residual lung capacity,12 thus lowering the baby’s work of  
breathing. The result is better compliance, reduced airway 
resistance, conservation of  surfactant, and stabilized chest 
and diaphragm.13 Bubble CPAP has been used in developed 
countries for decades.8 It reduces morbidity6 and mortality,5,8 
as well as the need for mechanical ventilation.6,7,9–11,14,15 It 
can be administered by trained nurses,14,16 and is safer than 
mechanical ventilation.6,14 It also reduces hospital stay6 and 
up-referrals.17 As a result CPAP is increasingly used as a first 
choice for ventilatory support in tertiary centres.9,14,18
A number of  observational studies have shown that CPAP 
can be safely implemented in low-resource settings using 
commercially available devices designed for high-resource 
settings.14,19–22 Unfortunately, the cost and complexity of  
currently available CPAP devices is prohibitive for many 
low-resource settings.
We recently developed a novel, low-cost bCPAP system for 
low-resource settings that can be assembled for approximately 
$350, a fifteen-fold cost reduction compared to the average 
stand-alone CPAP. The device delivers the same therapeutic 
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flow and pressure as bCPAP systems used in high-resource 
settings.23 Here, we report a study to evaluate the efficacy of  
the new low-cost bCPAP system in improving survival in 
newborns with severe respiratory distress at Queen Elizabeth 
Central Hospital in Malawi. Malawi has a population of  
15.4 million,24 with a preterm birth rate of  18%,25 neonatal 
mortality rate of  27 and infant mortality rate of  53 per 1000 
live births.26 The GDP is $805 per capita and 73.9% of  the 
population live on less than $1.25 per day.27 Queen Elizabeth 
Central Hospital is the main referral hospital in the southern 
region of  the country; each year, about 10,000 babies are 




The study protocol was approved by the University of  
Malawi College of  Medicine Research and Ethics Committee 
(P.05/11/1079) and the Institutional Review Boards at 
Baylor College of  Medicine (H-29059) and Rice University 
(11-198F) prior to study initiation. Written informed consent 
was obtained from parents or legal guardians before enrolling 
patients in the study.
Participants
This prospective, non-randomized controlled study, 
conducted at Queen Elizabeth Central Hospital, evaluated 
the efficacy and safety of  a novel, low-cost bCPAP device 
to treat neonatal respiratory illness in a low-resource setting. 
In Malawi, nasal oxygen from an oxygen concentrator is the 
standard of  care to treat respiratory insufficiency in neonates. 
The study evaluated whether bCPAP treatment improves 
survival for neonates with respiratory illness compared to 
standard nasal oxygen.
Infants admitted to the neonatal ward with severe respiratory 
distress as defined by the presence of  severe chest in-drawing, 
central cyanosis, wheezing, grunting, or nasal flaring were 
eligible to participate. In addition, patients had to weigh 1,000 
grams or more at enrollment, be breathing spontaneously, 
and be neurologically viable. The treating clinician also 
had to deem bCPAP appropriate treatment. Patients who 
presented with cleft palate, trachea-oesophageal fistula, 
diaphragmatic hernia, severe cardiac instability, and severe 
birth asphyxia were not eligible. Subjects were identified by 
clinicians working in the neonatal ward.
Procedures
Two low-cost bCPAP devices were installed in the ward. 
Figure 1 illustrates the study procedure and outcome groups. 
Patients were treated with bCPAP (treatment group) if  a 
bCPAP system and trained clinical staff  were available. If  
a bCPAP device or trained clinical staff  were not available, 
the patient received the local standard of  care, nasal oxygen 
(control group). This selection process was a sampling 
method whereby each patient was assigned to a group based 
on availability of  a bCPAP device and appropriate staff  
when treatment was initiated. In some cases, a child in the 
control group was transitioned from nasal oxygen to bCPAP 
treatment after entering the study when a bCPAP device 
became available.
The bCPAP device has been described previously [23]. 
It consists of  an adjustable flow generator, a pressure-
regulator, and a patient interface (Fig. S1). Two pumps 
provide continuous flow of  room air. The output of  an 
oxygen concentrator (Airsep, New Life Intensity, 10 LPM) is 
connected to an input port on the device; two flow regulators 
adjust the flow rate and proportion of  oxygen delivered. A 
pressure control tube submerged in a bottle of  water controls 
end-expiratory pressure. The device delivers a mixture of  
pressurized air and oxygen at flow rates ranging from 0–10 
L/min, pressures varying from 5–8 cm H2O, and oxygen 
ranging from 21–65%. The pumps are designed to operate 
for two years, and repair involves simple replacement of  a 
US $0.50 diaphragm.
The bCPAP delivered a pressurized air mixture via Hudson 
bi-nasal prongs that were attached to a stockinette hat using 
safety pins and elastic bands (Fig. S1). Nursing care for 
children receiving bCPAP included twice daily suctioning to 
clear the airways of  mucus. Sterile nasal saline drops were 
administered every four hours to reduce mucosal drying. 
Nasal oxygen was delivered from an oxygen concentrator 
(Airsep, New Life Intensity, 10 LPM) via standard nasal 
cannulae. The flow rate was set using a flow regulator and 
typically varied from 1–2 L/min.
Bubble CPAP and oxygen were administered until the 
treating clinician determined that therapy was no longer 
necessary. All patient care, with the exception of  respiratory 
support, was the same for the bCPAP and standard-of-care 
groups. Information, excluding personal identifiers, was 
recorded by clinical personnel on a standardized patient 
monitoring form and included age, date of  birth, presumed 
diagnosis, gender, weight, HIV status, vital signs, mode and 
tolerance of  feeding, physical examination and method and 
duration of  respiratory support. Vital signs were repeated 
one hour after recruitment (control group) or commencing 
bCPAP (treatment group), and twice daily afterward until 
discharge or death. Patients were monitored for progress and 
complications.
A study physician (K.K.) reviewed every child’s chart for 
study eligibility. Each participant was assigned a final primary 
diagnosis of  respiratory distress syndrome (RDS), congenital 
pneumonia, acquired pneumonia, meconium aspiration, 
transient tachypnoea of  the newborn (TTN), or stridor 
based on standard clinical criteria. Co-morbidities, including 
sepsis and jaundice, were also noted.
Statistical analysis
We planned to recruit a total of  50 patients in the treatment 
arm, matched 1:1 with controls, giving a total sample size 
of  100. This would, using a one-sided Fisher’s exact test, 
achieve at least 85% power to detect at least a 30% mortality 
reduction with bCPAP treatment compared with oxygen 
therapy with type I error = 0.05. We assumed mortality rates 
respectively in the treatment and control groups of  40% and 
70%. To allow for potential loss due to data collection errors, 
we planned to enroll up to 110 patients.
Data were recorded on paper forms, then entered into Excel 
and ported to SPSS for analysis.
We compared demographic data, primary diagnosis, co-
morbidities, and vital signs at entry for the two groups. A 
two-sided t-test for equality of  means was performed (equal 
variances not assumed) to determine whether differences 
in continuous variables were statistically significant; for 
categorical variables, a two-sided Fisher’s exact test was 
performed. Results were considered significant at the 5% 
level.
We calculated the survival rate with 95% confidence 
intervals (CIs) for the two groups. The hypothesis that the 
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asphyxia. Of  the 87 eligible participants, 62 were treated 
with bCPAP therapy and 25 received oxygen therapy. The 62 
neonates receiving bCPAP included nine who were initially 
assigned to the control group, but ultimately received bCPAP 
therapy when a device became available. Data were analysed 
for all 87 eligible neonates.
Table 1 summarizes the demographic and clinical covariates 
for the eligible neonates. Differences in the mean values of  
covariates for the group receiving bCPAP were not statistically 
significant compared to those for the control group with 
one exception: the fraction of  babies who required bag 
and mask ventilation before recruitment was higher in the 
bCPAP group than in the control group (p = 0.015). Most 
participants had very low birth weight (VLBW) and were 
born at QECH. Over 25% of  neonates in each group were 
from multiple births, and approximately 20% of  neonates in 
each group were exposed to HIV.
Figure 2 compares survival to discharge in the two groups. 
The survival rate in the control group was 44.0% (95% CI: 
26–63%); survival in the bCPAP group was 71.0% (95% 
CI: 59–81%) (p = 0.018). Without adjustment, bCPAP is 
associated with a 3.1 fold increase in odds of  survival (95% 
CI: 1.2–8.1, p = 0.02). Figure 2 also shows Kaplan-Meier 
survival curves of  cumulative survival vs. time following 
initiation of  treatment. These are different by the log rank 
test at p = 0.013.
Univariate logistic regression analysis indicated that five 
of  the covariates in Table 1 were related to survival: a 
primary diagnosis of  RDS (p = 0.002); co-morbidity of  
sepsis (p = 0.039); birth weight (p = 0.003); a birth weight in 
the VLBW range (p = 0.016); and gestational age (p = 0.023). 
rate of  survival was higher for babies receiving bCPAP than 
in the control group was tested using a one-sided Fisher’s 
exact test. Logistic regression was used to calculate the odds 
ratio for survival with 95% CIs for babies receiving bCPAP 
compared to standard care. Kaplan-Meier survival curves 
were calculated to show the probability of  survival following 
time from treatment initiation for the two groups.
Univariate logistic regression analysis was performed to 
explore whether demographic and clinical covariates were 
related to survival for all eligible participants. Results were 
considered significant at the 5% level using a two-sided 
Fisher’s exact test for categorical variables and a t-test for 
continuous variables.
Subgroup analysis was conducted for three of  the covariates 
that were related to survival (RDS, sepsis, VLBW). For each 
subgroup, the hypothesis that survival was higher for babies 
receiving bCPAP than in the control group was tested using a 
one-sided Fisher’s exact test. Logistic regression was used to 
calculate the odds ratio for survival with 95% CIs for babies 
receiving bCPAP compared to standard care. The subgroup 
analyses were not defined a priori.
Multiple logistic regression analysis was used to calculate the 
survival rates, odds ratio for survival and associated 95% 
CIs for babies receiving bCPAP compared to standard care, 
adjusted for differences in baseline values of  RDS, sepsis, 
VLBW.
Results
Eighty-nine neonates were enrolled from January to October 
2012 (Table 1). Chart review identified two neonates who did 
not meet eligibility criteria because they suffered severe birth 
We compared demographic data, primary diagnosis, co-
morbidities, and vital signs at entry for the two groups. A two-
sided t-test for equality of means was performed (equal variances
not as med) to determine whether differences in continuous
variables were statistically significant; for categorical variables, a
two-sided Fisher’s exact test was performed. Results were
considered significant at the 5% level.
We calculated the survival rate with 95% confidence intervals
(CIs) for the two groups. The hypothesis that the rate of survival was
higher for babies receiving bCPAP than i the control group was
tested using a one-sided Fisher’s exact test. Logistic regression was
used to calculate the odds ratio for survival with 95% CIs for babies
receiving bCPAP compared to standard care. Kaplan-Meier
survival curves were calculated to show the probability of survival
following time from treatment initiation for the two groups.
Univariate logistic regression analysis was performed to explore
whether demographic and clinical covariates were related to
survival for all eligible participants. Results were considered
significant at the 5% level using a two-sided Fisher’s exact test for
categorical variables and a t-test for continuous variables.
Subgroup analysis was conducted for three of the covariates that
were related to survival (RDS, sepsis, VLBW). For each subgroup,
the hypothesis that survival was higher for babies receiving bCPAP
than in the control group was tested using a one-sided Fisher’s
exact test. Logistic gression was used to calculate the odds ratio
for survival with 95% CIs for babies receiving bCPAP compared
to standard care. The subgroup analyses were not defined a priori.
Multiple logistic regression a alysis was us d to calculate the
urvival rates, odds ratio fo s rvival and associated 95% CIs for
babies receiving bCPAP compared to standard care, adjusted for
differences in baseline values of RDS, sepsis, VLBW.
Results
Eighty-nine neonates were enrolled from January to October
2012 (Table 1). Chart review identified two neonates who did not
meet eligibility criteria because they suffered severe birth asphyxia.
Of the 87 eligible participants, 62 were treated with bCPAP therapy
and 25 received oxygen therapy. The 62 neonates receiving bCPAP
included nine who were ini ially assigned to the control group, but
ultimately received bCPAP therapy when a device became
available. Data were analysed for all 87 eligible neonates.
Table 1 summarizes the demographic and clinical covariates for
the eligible neonates. Differences in the mean values of covariates
for the group receiving bCPAP were not statistically significant
compared to those for the control group with o e exception: the
fraction of babies who required bag and mask ventilation before
recruitment was higher in the bCPAP group than in the control
group (p = 0.015). Most participants had very low birth weight
(VLBW) and were born at QECH. Over 25% of neonates in each
group were from multiple births, and approximately 20% of
neonates in each group were exposed to HIV.
Figure 1. Flow chart summarizing study procedure and outcome groups.
doi:10.1371/journal.pone.0086327.g001
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Figure 2 compares survival to discharge in the two groups. The
survival rate in the control group was 44.0% (95% CI: 26–63%);
survival in the bCPAP group was 71.0% (95% CI: 59–81%)
(p = 0.018). Without adjustment, bCPAP is associated with a 3.1
fold increase in odds of survival (95% CI: 1.2–8.1, p = 0.02).
Figure 2 also shows Kaplan-Meier survival curves of cumulative
Table 1. Number of study participants and demographic data for subjects meeting eligibility criteria.
Demographic and Clinical Covariates Treatment Group: Nasal Oxygen Treatment Group: bCPAP
Transitioned from Nasal
Oxygen to bCPAP bCPAP
Number of study participants
Number of subjects completing study 25 9 55
Number of subjects meeting eligibility criteria 25 9 53
Gender
% Male 60.0% 44.4% 60.4%
% Female 40.0% 55.6% 39.6%
Gestational Age
Average (weeks) 33.0 weeks 32.0 weeks 33.2 weeks
Unknown (%) 12.0% 0.0% 9.4%
Average Birth Weight (kg) 1.68 kg 1.37 kg 1.79 kg
Very Low Birth Weight (.= 1.0 kg–,1.5 kg) (%) 52.0% 41.5% 77.8%
Low Birth Weight (.= 1.5 kg–,2.5 kg) (%) 28.0% 41.5% 22.2%
Birth Weight .= 2.5 kg (%) 20.0% 17.0% 0.0%
Location of birth
Queen Elizabeth Central Hospital (QECH) (%) 60.0% 55.6% 56.6%
Outside QECH (%) 32.0% 44.4% 32.1%
Unknown (%) 8.0% 0.0% 11.3%
Singletons vs. Multiples
Singletons (%) 52.0% 44.5% 73.6%
Multiples (%) 44.0% 44.4% 26.4%
Unknown (%) 4.0% 11.1% 0.0%
Received bag & mask ventilation prior to therapy?
Yes (%)* 4.0% 22.2% 24.5%
No (%) 88.0% 66.7% 54.7%
Unknown (%) 8.0% 11.1% 20.8%
HIV Status
Exposed 20.0% 33.3% 22.7%
Unexposed 64.0% 44.4% 67.9%
Unknown 16.0% 22.2% 9.4%
Entry vital statistics
Average entry heart rate (beats per minute (bpm)) 144 bpm 148 bpm 141 bpm
Average entry respiratory rate (bpm) 54 bpm 55 bpm 54 bpm
Average entry oxygen saturation (%) 92% 91% 88%
Primary Diagnosis
RDS 68.0% 100.0% 73.6%
Congenital Pneumonia 4.0% 0.0% 18.9%
Acquired Pneumonia 4.0% 0.0% 0.0%
Meconium Aspiration 8.0% 0.0% 5.7%
Transient Tachypnea of the Newborn 12.0% 0.0% 0.0%
Stridor 4.0% 0.0% 0.0%
Asphyxia 0.0% 0.0% 1.8%
Co-Morbidities
Sepsis 28.0% 44.4% 41.5%
*Difference in group receiving nasal oxygen and bCPAP significantly different (p = 0.015).
doi:10.1371/journal.pone.0086327.t001
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Further subgroup analyses were performed by birth weight, 
presence of  RDS and of  sepsis. As gestational age was not 
available for approximately 10% of  subjects, no subgroup 
analysis was conducted for this variable.
Figure 3 compares survival for eligible neonates with a 
primary diagnosis of  RDS and those with sepsis. For 
neonates with RDS, survival was 23.5% (95% CI: 9–49%) in 
the control group, compared to 64.6% (95% CI: 50–77%) in 
the bCPAP group (p = 0.006). None of  the seven neonates 
with sepsis in the control group survived, while survival was 
61.5% (95% CI: 42–78%) in the bCPAP group (p = 0.005).
Figure 4 shows survival rates for eligible neonates in the two 
groups, stratified by birth weight. Improvements in survival 
are greatest for VLBW infants (≥1.0–<1.5 kg); in whom 
survival was 15.4% (95% CI: 4–45%) in the control group 
compared to 65.5% (95% CI: 47–80%) in the bCPAP group 
(p≤0.001). For babies with low birth weight (≥1.5 kg–<2.5 
kg) and babies with birth weight ≥2.5 kg, differences in 
survival were not statistically different for the two groups.
Multiple logistic regression analysis was performed to adjust 
for baseline differences in RDS, sepsis, and VLBW; the 
adjusted survival rate for babies receiving bCPAP is 85% 
http://dx.doi.org/10.1371/journal.pone.0086327 PLoS One. 2014 Jan 29;9(1):e86327
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(95% CI: 69–94%), while that for standard care is 47% (95% 
CI: 23–73%) and bCPAP is associated with an adjusted 
6.5 fold increase in odds of  survival (95% CI: 1.9–22.7, 
p = 0.003).
Table 2 compares the secondary outcomes of  treatment 
time and duration of  hospital stay for all eligible subjects and 
for those who survived to discharge. On average, neonates 
receiving bCPAP spent five more days in the hospital and 
nearly three more days on treatment than those in the control 
group. On average, neonates who were transitioned from 
nasal oxygen to bCPAP spent twice as long in the hospital 
and twice as long on treatment as those who received bCPAP 
initially; the average delay in receiving bCPAP was 3.1 days. 
Similar trends in increased treatment and hospitalization 
time were seen for neonates who survived to discharge. The 
increase in treatment and hospitalization time in bCPAP 
could be explained by the differences in primary diagnosis 
between the two groups; children receiving bCPAP were 
more likely to suffer from RDS than those receiving nasal 
oxygen.
Only mild complications were associated with bCPAP (Table 
S1), including nasal irritation, facial irritation, and epistaxis. 
Similar complication rates were observed in the control 
group. No clinical diagnoses of  pneumothorax were made, 
but as routine x-rays and cranial ultrasound were unavailable, 
silent complications cannot be ruled out.
survival vs. time following initiation of treatment. These are
different by the log rank test at p = 0.013.
Univariate logistic regression analysis indicated that five of the
covariates in Table 1 were related to survival: a primary diagnosis
of RDS (p= 0.002); co-morbidity of sepsis (p = 0.039); birth weight
(p = 0.003); a birth weight in the VLBW range (p = 0.016); and
gestational age (p= 0.023). Further subgroup analyses were
performed by birth weight, presence of RDS and of sepsis. As
gestational age was not available for approximately 10% of
subjects, no subgroup analysis was conducted for this variable.
Figure 3 compares survival for eligible neonates with a primary
diagnosis of RDS and those with sepsis. For neonates with RDS,
survival was 23.5% (95% CI: 9–49%) in the control group,
compared to 64.6% (95% CI: 50–77%) in the bCPAP group
(p = 0.006). None of the seven neonates with sepsis in the control
group survived, while survival was 61.5% (95% CI: 42–78%) in
the bCPAP group (p = 0.005).
Figure 4 shows survival rates for eligible neonates in the two
groups, stratified by birth weight. Improvements in survival are
greatest for VLBW infants ($1.0–,1.5 kg); in whom survival was
15.4% (95% CI: 4–45%) in the control group compared to 65.5%
(95% CI: 47–80%) in the bCPAP group (p#0.001). For babies
with low birth weight ($1.5 kg–,2.5 kg) and babies with birth
weight $2.5 kg, differences in survival were not statistically
different for the two groups.
Multiple logistic regression analysis was performed to adjust for
baseline differences in RDS, sepsis, and VLBW; the adjusted
survival rate for babies receiving bCPAP is 85% (95% CI: 69–
94%), while that for standard care is 47% (95% CI: 23–73%) and
bCPAP is associated with an adjusted 6.5 fold increase in odds of
survival (95% CI: 1.9–22.7, p = 0.003).
Table 2 compares the secondary outcomes of treatment time
and duration of hospital stay for all eligible subjects and for those
who survived to discharge. On average, neonates receiving bCPAP
spent five more days in the hospital and nearly three more days on
treatment than those in the control group. On average, neonates
who were transitioned from nasal oxygen to bCPAP spent twice as
long in the hospital and twice as long on treatment as those who
received bCPAP initially; the average delay in receiving bCPAP
was 3.1 days. Similar trends in increased treatment and
hospitalization time were seen for neonates who survived to
discharge. The increase in treatment and hospitalization time in
bCPAP could be explained by the differences in primary diagnosis
between the two groups; children receiving bCPAP were more
likely to suffer from RDS than those receiving nasal oxygen.
Only mild complications were associated with bCPAP (Table
S1), including nasal irritation, facial irritation, and epistaxis.
Similar complication rates were observed in the control group. No
clinical diagnoses of pneumothorax were made, but as routine x-
rays and cranial ultrasound were unavailable, silent complications
cannot be ruled out.
Discussion
This study demonstrates the potential impact of introducing a
low-cost, appropriate bCPAP system in a low-resource setting
where standard therapy is nasal oxygen. Using bCPAP to treat
newborns with severe respiratory distress resulted in a 27%
absolute improvement in survival to discharge. The benefit was
more pronounced in neonates with VLBW, RDS, or sepsis. Only
24% of neonates with RDS treated with nasal oxygen survived to
discharge, compared to 65% receiving bCPAP, reflecting similar
rates of survival as observed in the US during the transition from
nasal oxygen to bCPAP for treatment of RDS [5].
The value of CPAP therapy for neonatal RDS is well-accepted
in high-resource settings but very few studies have examined the
value of CPAP therapy in resource-limited settings lacking
Figure 2. Overall survival of eligible study participants receiving nasal oxygen vs. bCPAP. (Left) Fraction of eligible study participants
who survived to discharge and received nasal oxygen or bCPAP. When treated with bCPAP, the survival rate of infants with severe respiratory distress
is significantly higher than for those treated with nasal oxygen (p = 0.018). Without adjustment, bCPAP is associated with a 3.1-fold increase in odds of
survival (confidence interval 1.2–8.1, significance= 0.02). (Right) Kaplan-Meier survival curves showing cumulative survival vs. days since treatment
initiation for infants with severe respiratory distress treated with bCPAP (n = 62) and those treated with nasal oxygen (n = 25).
doi:10.1371/journal.pone.0086327.g002
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advanced respiratory support [16,20,29]. These studies have either
included older children [16], examined immediate improvements
in clinical endpoints rather than survival to hospital discharge
[16], or been small, observational studies [20,29].
Our study was carried out in a typical low-resource setting using
a bCPAP that was conceived, designed and evaluated with input
from local physicians and nurses, ensuring that the device
addresses competencies and capacity of this under-resourced
environment [23], The technical performance of the device was
monitored throughout the study. Therapeutic flow and pressure
met performance standards reliably without preventive mainte-
nance, a d no device failures oc urred. In contrast, 40% of study
oxyg n concentrators failed during this same period wh n circuit
boards were damaged by line voltage spikes. To meet cost and
infrastructure constraints, the bCPAP device did not heat or
humidify the mix of pressurized air and oxygen delivered via the
nasal prongs. Instead, humidification was provided through
routine use of nas l saline drops. This did not appear to result
in significant omplications (Table S1).
Our study has a number of limitations. As bCPAP is known to
be an effective therapy [5,6,8], we did not perform a randomised
trial. Instead, the decision to treat with bCPAP was based on
availability of a bCPAP device. This design allowed potential bias.
We planned to recruit equal numbers of patients in each arm to
detect a difference between the two groups. However, since
allocation of CPAP to eligible subjects was based on device
availability actual enrollment was dependent on available equip-
ment and staffing resources. Our original estimate was that CPAP
devices would be available approximately half the time needed. To
allow for potential loss due to data collection errors, we planned to
enroll up to 110 patients. In practice, CPAP devices were available
more frequently than not and thus more study participants
received CPAP than nasal oxygen. The study was stopped when
over 60 participants received CPAP; at this point, the projected
number of CPAP patients had been enrolled plus the entire
additional allowed margin to account for data loss.
In addition, this design could result in treating infants with more
severe illness with bCPAP and those with less severe illness with
nasal oxygen. Indeed a significantly higher proportion of infants
treated with bCPAP required resuscitation prior to therapy
(24.5%) than those who received nasal oxygen (4.0%). We
monitored the status of children receiving nasal oxygen. Nine of
them were transitioned to bCPAP when they failed to improve and
a device became available. The outcomes of these nine children
were analysed with the bCPAP group. All of the babies in the
Figure 3. Survival of participants with RDS and sepsis receiving nasal oxygen vs. bCPAP. (Left) Fraction of eligible study subjects with a
primary diagnosis of respiratory distress syndrome (RDS) who survived to discharge and received nasal oxygen or bCPAP. (Right) Fraction of eligible
study subjects with a co-morbidity of sepsis who survived to discharge and received nasal oxygen or bCPAP.
doi:10.1371/journal.pone.0086327.g003
Figure 4. Survival of participants by birthweight receiving
nasal oxygen vs. bCPAP. Fraction of eligible study subjects who
survived to discharge and received nasal oxygen or bCPAP, stratified by
birth weight. Results are reported for subjects with very low birth
weight (.= 1.0 kg to ,1.5 kg), low birth weight (.= 1.5 kg to
,2.5 kg) and birth weights greater than or equal to2.5 kg.
doi:10.1371/journal.pone.0086327.g004
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survival to hospital discharge,16 or been small, observational 
studies.20,29
Our study was carried out in a typical low-resource setting 
using a bCPAP that was conceived, designed and evaluated 
with input from local physicians and nurses, ensuring that the 
device addresses competencies and capacity of  this under-
resourced environment.23 The technical performance of  the 
device was monitored throughout the study. Therapeutic flow 
and pressure met performance standards reliably without 
preventive maintenance, and no device failures occurred. In 
contrast, 40% of  study oxygen concentrators failed during 
this same period when circuit boards were damaged by line 
voltage spikes. To meet cost and infrastructure constraints, 
the bCPAP device did not heat or humidify the mix of  
pressurized air and oxygen delivered via the nasal prongs. 
Instead, humidification was provided through routine use of  
nasal saline drops. This did not appear to result in significant 
complications (Table S1).
Our study has a number of  limitations. As bCPAP is 
known to be an effective therapy,5,6,8 we did not perform a 
randomised trial. Instead, the decision to treat with bCPAP 
was based on availability of  a bCPAP device. This design 
allowed potential bias. We planned to recruit equal numbers 
of  patients in each arm to detect a difference between the 
two groups. However, since allocation of  CPAP to eligible 
subjects was based on device availability actual enrollment 
was dependent on available equipment and staffing resources. 
Our original estimate was that CPAP devices would be 
available approximately half  the time needed. To allow for 
potential loss due to data collection errors, we planned to 
enroll up to 110 patients. In practice, CPAP devices were 
available more frequently than not and thus more study 
participants received CPAP than nasal oxygen. The study 
was stopped when over 60 participants received CPAP; at 
this point, the projected number of  CPAP patients had been 
enrolled plus the entire additional allowed margin to account 
for data loss.
In addition, this design could result in treating infants 
with more severe illness with bCPAP and those with less 
severe illness with nasal oxygen. Indeed a significantly 
higher proportion of  infants treated with bCPAP required 
resuscitation prior to therapy (24.5%) than those who received 
nasal oxygen (4.0%). We monitored the status of  children 
Discussion
This study demonstrates the potential impact of  introducing 
a low-cost, appropriate bCPAP system in a low-resource 
setting where standard therapy is nasal oxygen. Using bCPAP 
to treat newborns with severe respiratory distress resulted in 
a 27% absolute improvement in survival to discharge. The 
benefit was more pronounced in neonates with VLBW, RDS, 
or sepsis. Only 24% of  neonates with RDS treated with nasal 
oxygen survived to discharge, compared to 65% receiving 
bCPAP, reflecting similar rates of  survival as observed in the 
US during the transition from nasal oxygen to bCPAP for 
treatment of  RDS.5
The value of  CPAP therapy for neonatal RDS is well-
accepted in high-resource settings but very few studies have 
examined the value of  CPAP therapy in resource-limited 
settings lacking advanced respiratory support.16,20,29 These 
studies have either included older children,16 examined 
immediate improvements in clinical endpoints rather than 
advanced respiratory support [16,20,29]. These studies have either
included older children [16], examined immediate improvements
in clinical endpoints rather than survival to hospital discharge
[16], or been small, observational studies [20,29].
Our study was carried out in a typical low-resource setting using
a bCPAP that was conceived, designed and evaluated with input
from local physicians and nurses, ensuring that the device
addresses competencies and capacity of this under-resourced
environment [23], The technical performance of the device was
monitored throughout the study. Therapeutic flow and pressure
met performance standards reliably without preventive mainte-
nance, and no device failures occurred. In contrast, 40% of study
oxygen concentrators failed during this same period when circuit
boards were damaged by line voltage spikes. To meet cost and
infrastructure constraints, the bCPAP device did not heat or
humidify the mix of pressurized air and oxygen delivered via the
nasal prongs. Instead, humidification was provided through
routine use f nasal s line drops. This did not appear to result
in significant complications (Table S1).
Our study has a number of limitations. As bCPAP is known to
be an effective therapy [5,6,8], we did not perform a randomised
trial. Instead, the decision to treat with bCPAP was based on
availability of a bCPAP device. This design allowed potential bias.
We planned to recruit equal numbers of patients in each arm to
det ct a difference between the two groups. However, since
allocation of CPAP to eligible subjects was based on device
availability actual enrollment was dependent on available equip-
ment and staffing resources. Our original estimate was that CPAP
devices would be available approximately half the time needed. To
allow for potential loss due to data collection errors, we planned to
enroll up to 110 patients. In practice, CPAP devices were available
more frequently than not and thus more study participants
received than nasal oxygen. The study was stopped when
over 60 participants received CPAP; at this point, the projected
number of CPAP patients had been enrolled plus the entire
additional allowed margin to account for data loss.
In addition, this design could result in treating infants with more
severe illness with bCPAP and those with less severe illness with
nasal oxygen. Indeed significantly higher proportion of infants
treated with CPAP required resuscitation prior to therapy
(24.5%) than those who received nasal oxygen (4.0%). We
monitored the status of children receiving nasal oxygen. Nine of
them were transitioned to bCPAP when they failed to improve and
a device became available. The outcomes of these nine children
were analysed with the bCPAP group. All of the babies in the
Figure 3. Survival of participants with RDS and sepsis receiving nasal oxygen vs. bCPAP. (Left) Fraction of eligible study subjects with a
primary diagnosis of respiratory distress syndrome (RDS) who survived to discharge and received nasal oxygen or bCPAP. (Right) Fraction of eligible
study subjects with a co-morbidity of sepsis who survived to discharge and received nasal oxygen or bCPAP.
doi:10.1371/journal.pone.0086327.g003
Figure 4. Survival of participants by birthweight receiving
nasal oxygen vs. bCPAP. Fraction of eligible study subjects who
survived to discharge and received nasal oxygen or bCPAP, stratified by
birth weight. Results are reported for subjects with very low birth
weight (.= 1.0 kg to ,1.5 kg), low birth weight (.= 1.5 kg to
,2.5 kg) and birth weights greater than or equal to2.5 kg.
doi:10.1371/journal.pone.0086327.g004
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CPAP group received CPAP within 36 hours of being identified as
needing CPAP, with a majority receiving it immediately. Five of
the nine babies in the group that transitioned to CPAP also
received CPAP treatment within 36 hours of being identified as
needing CPAP. Because, in general, preterm infants who survive
the first few postnatal days have an increased chance of long-term
survival, transitioning babies into the CPAP group after a few days
in the oxygen group might have created bias in favour of CPAP.
To account for this potential bias, we performed a per-protocol
analysis, comparing outcomes for infants who received bCPAP to
those who received nasal oxygen; babies who initially received
oxygen but were later transitioned to CPAP are not included in the
per-protocol analysis. The survival rate in the control group was
44.0%; survival in the bCPAP group was 69.8% (p= 0.014). For
neonates with RDS, survival was 23.5% in the control group,
compared to 61.5% in the bCPAP group (p= 0.004). Again,
improvements in survival were found to be greatest for VLBW
infants ($1.0–,1.5 kg); in whom survival was 15.4% in the
control group compared to 57.1% in the bCPAP group
(p = 0.006).
Analysing these nine babies as part of the standard care group,
analogous to intent-to-treat, we find that 69.8% (37/53) of
children receiving bCPAP survived to discharge, compared to
52.9% (18/34) for standard care; the improvement in survival
approaches significance (p= 0.087). Finally, we did not determine
the optimal time to initiate or terminate treatment with bCPAP.
Additional studies are needed to determine if earlier commence-
ment of bCPAP could further improve outcomes in this setting.
Neonatal deaths account for 41% of global child mortality; the
neonatal mortality rate has changed little in the last decade [30]. If
our results are generalizable, we estimate that on the African
continent, where nearly one million babies die each year within a
week of birth [31], providing low-cost bCPAP in central and
district hospitals could prevent 178,000 neonatal deaths. While the
cost of the bCPAP device has been reduced, the cost and
availability of consumables, staff support and support equipment
remain a barrier to scale-up. Nonetheless, implementing such a
system has the potential to improve neonatal care and health
outcomes in low-resource settings.
Supporting Information
Figure S1 Photograph showing bubble CPAP device
used in the study. bCPAP was delivered using Hudson prongs
secured to a stretchy hat with safety pins and elastic bands. The
bCPAP delivered a blended mix of air and oxygen from an oxygen
concentrator at flow rates varying from 0–10 L/min and pressures
ranging from 5–8 cm H2O.
(TIF)
Table S1 Fraction of eligible participants in each
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Table 2. Average duration of treatment and hospital stay (+/2 standard deviation) for eligible subjects and survivors versus
treatment group.
All eligible neonates Nasal Oxygen bCPAP
Transitioned from nasal oxygen to
bCPAP
Average hospital stay (days) 9.10 (9.70) 14.13 (10.87) 22.00 (14.14)
Average time from study entry to treatment with bCPAP (days) NA 0.19 (0.42) 3.11 (3.18)
Average total time on treatment (days) 4.00 (4.37) 6.91 (5.37) 13.94 (11.45)
Average time receiving nasal oxygen (days) 4.00 (4.37) 1.84 (3.04) 9.83 (9.68)
Average time receiving bCPAP (days) NA 5.07 (3.66) 4.11 (2.87)
Survivors Nasal Oxygen bCPAP
Transitioned from nasal oxygen to
bCPAP
Average hospital stay (days) 13.27 (11.00) 18.89 (9.60) 27.57 (10.83)
Average time from study entry to treatment with bCPAP (days) NA 0.27 (0.49) 3.86 (3.24)
Average total time on treatment (days) 3.59 (3.05) 8.69 (5.41) 17.36 (10.77)
Average time receiving nasal oxygen (days) 3.59 (3.05) 2.58 (3.36) 12.43 (9.50)
Average time receiving bCPAP (days) NA 6.11 (3.72) 4.93 (2.73)
doi:10.1371/journal.pone.0086327.t002
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CPAP group received CPAP within 36 hours of being identified as
needing CPAP, with a majority receiving it immediately. Five of
the nine babies in the group that transitioned to CPAP also
received CPAP treatment within 36 hours of being identified as
needing CPAP. Because, in general, preterm infants who survive
the first few postnatal days have an increased chance of long-term
survival, transitioning babies into the CPAP group after a few days
in the oxygen group might have created bias in favour of CPAP.
To account for this potential bias, we performed a per-protocol
analysis, comparing outcomes for infants who received bCPAP to
those who received nasal oxygen; babies who initially received
oxygen but were later transitioned to CPAP are not included in the
per-protocol analysis. The survival rate in the control group was
44.0%; survival in the bCPAP group was 69.8% (p= 0.014). For
neonates with RDS, survival was 23.5% in the control group,
compared to 61.5% in the bCPAP group (p= 0.004). Again,
improvements in survival were found to be greatest for VLBW
infants ($1.0–,1.5 kg); in whom survival was 15.4% in the
control group compared to 57.1% in the bCPAP group
(p = 0.006).
Analysing these nine babies as part of the standard care group,
analogous to intent-to-treat, we find that 69.8% (37/53) of
children receiving bCPAP survived to discharge, compared to
52.9% (18/34) for standard care; the improvement in survival
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district hospitals could prevent 178,000 neonatal deaths. While the
cost of the bCPAP device has been reduced, the cost and
availability of consumables, staff support and support equipment
remain a barrier to scale-up. Nonetheless, implementing such a
system has the potential to improve neonatal care and health
outcomes in low-resource settings.
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used in the study. bCPAP was delivered using Hudson prongs
secured to a stretchy hat with safety pins and elastic bands. The
bCPAP delivered a blended mix of air and oxygen from an oxygen
concentrator at flow rates varying from 0–10 L/min and pressures
ranging from 5–8 cm H2O.
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Table 2. Average duration of treatment and hospital stay (+/ standard deviation) for eligible subjects and survivors versus
treatment group.
All eligible neonates Nasal Oxygen bCPAP
Transitioned from nasal oxygen to
bCPAP
Average hospital stay (days) 9.10 (9.70) 14.13 (10.87) 22.00 (14.14)
Average time from study entry to treatment with bCPAP (days) NA 0.19 (0.42) 3.11 (3.18)
Average total time on treatment (days) 4.00 (4.37) 6.91 (5.37) 13.94 (11.45)
Average time receiving nasal oxygen (days) 4.00 (4.37) 1.84 (3.04) 9.83 (9.68)
Average time receiving bCPAP (days) NA 5.07 (3.66) 4.11 (2.87)
Survivors Nasal Oxygen bCPAP
Transitioned from nasal oxygen to
bCPAP
Average hospital stay (days) 13.27 (11.00) 18.89 (9.60) 27.57 (10.83)
Average time from study entry to treatment with bCPAP (days) NA 0.27 (0.49) 3.86 (3.24)
Average total time on treatment (days) 3.59 (3.05) 8.69 (5.41) 17.36 (10.77)
Average time receiving nasal oxygen (days) 3.59 (3.05) 2.58 (3.36) 12.43 (9.50)
Average time receiving bCPAP (days) NA 6.11 (3.72) 4.93 (2.73)
doi:10.1371/journal.pone.0086327.t002
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Mild facial irritation, < 1 day duration  3 (12%)  1 (1.9%)  0 (0.0%) 
Mild nasal irritation, <3 day duration  1 (4.0%)  7 (13.2%)  2 (22.2%) 
Mild epistaxis  1 (4.0%)  6 (11.3%)  2 (22.2%) 
 
